Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06467305 · ClinicalTrials.gov registry record · NA

Speech Motor Learning and Retention (Aim 1)

A NA study of Speech, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
160
Enrollment target
1
Study location

NCT06467305: Recruiting NA study of Speech, sponsored by Yale University.

NCT06467305 is a NA study of Speech that is actively recruiting participants, run by Yale University. The registered enrollment target is 160 participants, roughly in line with the 158-participant average among 9 other Speech trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06467305, a NA study of Speech, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well. The strategy for the proposed research is to identify individual brain areas that contribute causally to retention by disrupting their activity with transcranial magnetic stimulation (TMS). Investigators will also use functional magnetic resonance imaging (fMRI) which will enable identification of circuit-level activity which predicts either learning or retention of new movements, and hence test the specific contributions of candidate sensory and motor zones. In other studies, investigators will record sensory and motor evoked potentials over the course of learning to determine the temporal order in which individual sensory and cortical motor regions contribute. The goal here is to identify brain areas in which learning-related plasticity occurs first and which among these areas predict subsequent learning.

Primary Outcome

Audapter software will be used to alter the first and second formant frequencies of the spoken words and this is played back to subjects through headphones. Subjects will be tested both with unaltered feedback and with abruptly introduced frequency shifts.The change in the first (F1) and second format frequency (F2) values will be assessed using Praat.

Conditions Studied

Interventions

  • DEVICE continuous theta-burst stimulation (cTBS)
  • BEHAVIORAL Adaptation

Study Locations (1)

Connecticut

  • Yale Child Study Center - New Haven

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2024-10-01
Est. Completion 2029-05-31
Phase NA
Yale University

1,492 total trials

What NCT06467305 shows while recruiting

NCT06467305 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 158-participant average among 9 other Speech trials with a reported enrollment target.

The record links to 1 condition, with Speech appearing as the primary indexed condition, and to 2 interventions - of which continuous theta-burst stimulation (cTBS) is the first listed.

NCT06467305 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT06467305 about?

NCT06467305 is a clinical study titled "Speech Motor Learning and Retention (Aim 1)". The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well. The strategy for the proposed research is ...

What is the current status of trial NCT06467305?

This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2024-10-01. Estimated completion is 2029-05-31.

What conditions does trial NCT06467305 study?

This clinical trial studies the following conditions: Speech.

What interventions are being tested in trial NCT06467305?

The interventions under investigation include: continuous theta-burst stimulation (cTBS) (DEVICE), Adaptation (BEHAVIORAL).

Who is sponsoring clinical trial NCT06467305?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06467305 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Speech

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06467305's enrollment target sits among peer trials

160 3rd of 9 higher than 7 of 9 other Speech trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Speech trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06467305, the US trial registry maintained by the National Library of Medicine. NCT06467305 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.